Treatment of Cushing's Syndrome

Introduction to Cushing's Syndrome Management

The American College of Endocrinology recommends transsphenoidal pituitary surgery as the definitive first-line treatment for Cushing's disease, as it addresses the root cause and offers the best chance for remission in patients with pituitary-driven hypercortisolism 1, 2

The Endocrine Society suggests confirming the diagnosis by obtaining pituitary MRI to identify an adenoma, as this will guide surgical approach 1
Transsphenoidal surgery should be performed by an experienced pituitary surgeon to remove the adenoma, as this addresses the root cause and offers the best chance for remission 2

The European Society of Endocrinology recommends osilodrostat or metyrapone for rapid cortisol normalization, with response typically seen within hours 1
Ketoconazole is an alternative that works within a few days and normalizes cortisol in approximately 64% of patients, though it requires liver function monitoring 1, 2
For patients desiring future pregnancy, cabergoline may be considered as it has a more favorable profile in this context, though it has slower onset and lower efficacy 1

The American Association of Clinical Endocrinologists recommends bisphosphonates, such as alendronate, to induce rapid BMD improvement and prevent further bone loss in patients with osteoporosis 3, 4
Supplementing with vitamin D and calcium is necessary to support bone recovery 3
Spironolactone or eplerenone are first-line agents for hypertension management, as they block mineralocorticoid receptor activation from excess cortisol 5, 6
Treating hypertension according to high cardiovascular risk guidelines is crucial, as patients with Cushing's syndrome have 4.1 to 16-fold increased mortality from cardiovascular events 3, 6
Initiating appropriate glucose-lowering therapy immediately, with consideration of GLP-1 receptor agonists or DPP-4 inhibitors, is necessary for hyperglycemia management 5

Postoperative corticosteroid supplementation is required until recovery of the hypothalamus-pituitary-adrenal axis 2
Monitoring for clinical features of adrenal insufficiency, including fatigue, weakness, nausea, hypotension, and hypoglycemia, is necessary during the recovery period 5
Continuing bisphosphonate therapy is necessary, as BMD improvement is delayed and often incomplete even after successful surgery 3
Screening for growth hormone deficiency 6-12 months post-surgery is necessary, as GHD occurs in 50-60% of patients within 2 years and can worsen bone loss, myopathy, and quality of life 4, 3

Assuming this is exogenous Cushing's syndrome without ruling out endogenous causes can lead to delayed diagnosis and treatment 5
Delaying bisphosphonate therapy waiting for cortisol normalization alone can lead to slow bone recovery and elevated fracture risk 3
Using pasireotide as first-line therapy in patients with elevated A1C can worsen hyperglycemia 1
Undertreating hypertension can lead to increased mortality from cardiovascular events 3

Bilateral adrenalectomy should be reserved for severe refractory cases or life-threatening emergencies, with awareness of higher risk of Nelson syndrome (corticotroph tumor progression) 2
Combination medical therapy, such as ketoconazole plus metyrapone, may be necessary to maximize adrenal blockade, though this increases risk of adverse effects including QTc prolongation 1